{"cmr":"uk-cm-kg/LSE/AZN","since":null,"total":147,"cursor":0,"limit":50,"next_cursor":50,"events":[{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-11-07","event_type":"ch_capital","title":"capital allotment shares — 2026-10-28","ch_filing_type":"capital","source":"Companies House","url":"https://find-and-update.company-information.service.gov.uk/company/02723534/filing-history/MzU1NDE5NzIxNmFkaXF6a2N4/document?format=pdf&download=0","read_by":"Companies House REST API (filing history)","detail":"form SH01; category capital","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"qqVTQsRl867uf4uJA5m4veEZcp23ETmlwiodeOIDdOt5z5JL8Kgd9DG1ubFh52neUcNgrb3zZ3DLI-LLFYwNAA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-11-02","event_type":"corporate_action","title":"Admission of Further Securities to Trading","rns_category":"Admission of Further Securities to Trading","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/admission-of-further-securities-to-trading/9854040","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"TN_mq8_75WFHUTAdi5blVvBq5gRZcIKFqVoetveapu-Kf2N22eTGeRtiFiyJxAvTi8YjGqMstMyWQxh6PWqtDg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-11-02","event_type":"corporate_action","title":"Total Voting Rights","rns_category":"Total Voting Rights","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/total-voting-rights/9854003","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"gXRh93zIFZDtsFbaqQ3t3ZVt5TT24VLoKOqQjS-jjAOYYLB3-LayaRSYAd3xO4du-8f7qsZ7rfSbmS4nnYaHAw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-10-30","event_type":"regulatory_announcement","title":"3rd Quarter Results","rns_category":"3rd Quarter Results","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/3rd-quarter-results/9849221","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"q53q26TNqi3r0YFjbYMYR7bOAMDQIDEqLySNlOVZ_PQPTLE1yO45ML7lsaT2KEeIFl1BlX0ZmHI8WILof5jBBA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-10-27","event_type":"regulatory_announcement","title":"Enhertu approved in EU for HER2-positive eBC","rns_category":"Enhertu approved in EU for HER2-positive eBC","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/enhertu-approved-in-eu-for-her2-positive-ebc/9843216","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"lvL1LwigVsHfMmjhddzVQiJbx72kNLi1ux6bWHgNl2A3B9Fqv2iYB2yYoiSKod433l3lTDGXd0KdX5C4gEacDA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-10-26","event_type":"early_warning","title":"Holding(s) in Company","rns_category":"Holding(s) in Company","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/holding-s-in-company/9841939","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"u7ZXsucLpDkpgqnFl8b9wNJmGwGpZPBgHWid59oOxrrtJS4F7jzxJOFX1S2hqUJm2dxGXYp2JoilKl4_1uG1DQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-10-22","event_type":"regulatory_announcement","title":"Ultomiris approved in US in IgAN","rns_category":"Ultomiris approved in US in IgAN","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/ultomiris-approved-in-us-in-igan-/9835295","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"NaMZOK0abQWUTRvJErURZ7Kr34vjvgpH6GrWjqE2npi5YBVwX1VpHVZ7dRdRxaIGw_99falleTz1ZpVoRIluDw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-10-05","event_type":"ch_capital","title":"capital allotment shares — 2026-09-23","ch_filing_type":"capital","source":"Companies House","url":"https://find-and-update.company-information.service.gov.uk/company/02723534/filing-history/MzU0ODIzNzExN2FkaXF6a2N4/document?format=pdf&download=0","read_by":"Companies House REST API (filing history)","detail":"form SH01; category capital","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"rPfABJ_4Y8oUarhXMUbB-gYavGwTDvsvOL5ZvfX6riB7nTakRl3nlvWSiCwwyA87ghBUQlpX1nlOYGpZafXLAA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-10-05","event_type":"regulatory_announcement","title":"AstraZeneca completes equity investment in Summit","rns_category":"AstraZeneca completes equity investment in Summit","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/astrazeneca-completes-equity-investment-in-summit/9806986","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"ZXfNN-TK4vlCO6WnbLr82rwFGUQI7fLPZlgbBVTceOns27UMjwKWx8r2rIROlcSAD8NxAZ7dzCOgbRONHb2dBA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-10-02","event_type":"regulatory_announcement","title":"AZ & DS collaboration with Summit for Datroway","rns_category":"AZ & DS collaboration with Summit for Datroway","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/az-ds-collaboration-with-summit-for-datroway/9803807","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"a8Qq0Yxi9cx4JZ1mJoMrH7_q9FPfymYzkRcbgPdAEGhbaEZsXkbV72miy6vzWzVWSLSq-Dtn1t2zHEDeHzWFBw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-09-10","event_type":"ch_officer_change","title":"appoint person director company with name date — Wan Ling Martello; 2026-09-01","ch_filing_type":"officers","source":"Companies House","url":"https://find-and-update.company-information.service.gov.uk/company/02723534/filing-history/MzU0MzY4NjA3OWFkaXF6a2N4/document?format=pdf&download=0","read_by":"Companies House REST API (filing history)","detail":"form AP01; category officers","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"IFEgixYbACQUjHQR_DguH0Exri_syLsnJyGBM6MWGHlZV2akgXjLmCYm8kO8VEKHTsBMxsx6WK9m35KzoM_CCg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-09-08","event_type":"regulatory_announcement","title":"Imfinzi+Imdelltra improved OS in small cell lung","rns_category":"Imfinzi+Imdelltra improved OS in small cell lung","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/imfinzi-imdelltra-improved-os-in-small-cell-lung/9761376","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"B8k0QI-dC09_MJB0PKiwRSQFPxaI_ZsHhM402NwQ4YNvd1iv-rFHcvjgqemCiAjrh1TP4Fid_Io1NT9WG9QnBQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-09-07","event_type":"regulatory_announcement","title":"Etcamah approved in the US for HR+ breast cancer","rns_category":"Etcamah approved in the US for HR+ breast cancer","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/etcamah-approved-in-the-us-for-hr-breast-cancer-/9757529","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"PU8od2jgLKSw1bTylQ8awjWITbz_pxyoM6i1GqL5uvAz3a8jbdetxg9cBj4_3BpnPU092tKi7dfNJ65s2oG0Cw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-09-02","event_type":"ch_capital","title":"capital allotment shares — 2026-08-19","ch_filing_type":"capital","source":"Companies House","url":"https://find-and-update.company-information.service.gov.uk/company/02723534/filing-history/MzU0MDU2MjgwNmFkaXF6a2N4/document?format=pdf&download=0","read_by":"Companies House REST API (filing history)","detail":"form SH01; category capital","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"UGT9XaGC3SM452j8w_nHBdzhNCYMahHoqCcAUJNqHbWjq8qg96wlGurpEg5M--3XEO1zaxV1kO8c641g3SYAAw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-09-01","event_type":"corporate_action","title":"Admission of Further Securities to Trading","rns_category":"Admission of Further Securities to Trading","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/admission-of-further-securities-to-trading/9750008","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"itEG0uxHiCaZrQNefv5logcQqdNIYhnWGPC5dHTBghFIIvGQ2ozbwc3GUSp7dYyZ7QHVXusFbwPFuUOMj6U0Bw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-09-01","event_type":"corporate_action","title":"Total Voting Rights","rns_category":"Total Voting Rights","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/total-voting-rights/9749978","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"9EwB4XlXuufE-YkIoDH6UoMqfk5mx0O3f2TtvbSxd4RIsd19h18w2vtC5sroLCA52dUaDrfEkeyL76LC2vkRDQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-09-01","event_type":"corporate_action","title":"Admission to Trading - €2.55 billion bond offering","rns_category":"Admission to Trading - €2.55 billion bond offering","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/admission-to-trading-2-55-billion-bond-offering/9749422","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"rOytIunEqyFU6zeIyIy5rwQ5WmLbL22asWRce-WmGW8oibxPSCQInNPqHFFyTIzVIdo8cuDy2vz6bOna5nagAA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-09-01","event_type":"director_dealing","title":"Directorate change","rns_category":"Directorate change","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/directorate-change/9748143","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"G8jO3kduLLigZIAs1fgbmUXAJjfKxHmvvhKW_dxCVP4xOGCKjl1G82pKqIbZVSSLhn58Ovf0CaqLfgkfxsgsCA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-09-01","event_type":"regulatory_announcement","title":"Enhertu approved in EU for 1L HER2-positive mBC","rns_category":"Enhertu approved in EU for 1L HER2-positive mBC","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/enhertu-approved-in-eu-for-1l-her2-positive-mbc/9748654","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"n1IZ8NP1eDLRCzLvESbHSYCPYKBzgxiv-jRSulrg_NdIyzCp4fMri0Z3mWgCxpDqVDKgGIwzbor8Ouk-rwfdBQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-09-01","event_type":"regulatory_announcement","title":"AstraZeneca completes agreement for Zegfrovy","rns_category":"AstraZeneca completes agreement for Zegfrovy","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/astrazeneca-completes-agreement-for-zegfrovy/9748110","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"tUOQ0JjIu3SxZdimJeQKpDXI05HgOh10DENeHAcsS93qPHKUMqH4aO5DsKnVtnedMf4I3L6NPTlJUKxgsojbBA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-09-01","event_type":"regulatory_announcement","title":"Tagrisso + Orpathys improved PFS in 1L EGFRm lung","rns_category":"Tagrisso + Orpathys improved PFS in 1L EGFRm lung","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/tagrisso-orpathys-improved-pfs-in-1l-egfrm-lung/9747530","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"I1b9VQPH04_cVDbplahU_SUA4w67gmLvcx6CUV3P0AXXltN9MhC3oNu9aVUUh-q9IQl-Xn1MyvaXO051LSoFCw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-08-27","event_type":"regulatory_announcement","title":"Tezspire CROSSING trial met primary endpoints","rns_category":"Tezspire CROSSING trial met primary endpoints","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/tezspire-crossing-trial-met-primary-endpoints/9742178","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"tICFfZxPVyQSo2Oe5zoXioqguRp7_N46Fb87Hq131zSdl8OddRnm0fpOpnWhUlccJ3brHUlmuaN6knr9jLquCg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-08-25","event_type":"regulatory_announcement","title":"AstraZeneca prices a €2.55 billion bond offering","rns_category":"AstraZeneca prices a €2.55 billion bond offering","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/astrazeneca-prices-a-2-55-billion-bond-offering/9737668","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"aLZSuEiQnKJDqhjXNJ8qNsc-L5BDjmtxQ6HFbn5VT6xCe4JWF2SvDt3Y3zgpzSRSyXEncRW5mhEL_wFAEK7gAw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-08-19","event_type":"director_dealing","title":"Director/PDMR Shareholding","rns_category":"Director/PDMR Shareholding","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/director-pdmr-shareholding/9729953","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"F2RVSmR9K2kJ0iWUWcMrEwOQWw3YU0b4nZWdXVOD2-3kixYybLueKHkROehR6O0oZ-ZwsIwHjwqSWueow_fjDw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-08-17","event_type":"regulatory_announcement","title":"Enhertu improved PFS in 1L HER2m lung cancer","rns_category":"Enhertu improved PFS in 1L HER2m lung cancer","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/enhertu-improved-pfs-in-1l-her2m-lung-cancer/9724621","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"463cW30uh5V6SxfAhr9KA4na1vQAnkSQAxlICRpbR54b_-q9ceuPuqhw8nww5ofI6Rlv3pEhvED7dIyHucajBA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-08-17","event_type":"regulatory_announcement","title":"Update on eVOLVE-Lung02 Phase III trial","rns_category":"Update on eVOLVE-Lung02 Phase III trial","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/update-on-evolve-lung02-phase-iii-trial/9724094","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"wALym79nlYyxJNj0lRzonweUZExJHaYrrxAxQyJmOS0_QThppR3cieRUH-QzzUlAyBrj1BrhFzAGMftlrKnrBQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-08-17","event_type":"regulatory_announcement","title":"Tagrisso+Orpathys improved PFS & OS in EGFRm lung","rns_category":"Tagrisso+Orpathys improved PFS & OS in EGFRm lung","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/tagrisso-orpathys-improved-pfs-os-in-egfrm-lung/9723848","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"Ho1MYs4UpUHOMYQsD4bkt7Vf03hY0sgAqaH3ubICJzWPGuPAdlyNPJ8vWTsqJXq4WZmmOTkOoDvu7dbNiai5DA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-08-04","event_type":"ch_capital","title":"capital allotment shares — 2026-07-15","ch_filing_type":"capital","source":"Companies House","url":"https://find-and-update.company-information.service.gov.uk/company/02723534/filing-history/MzUzNTc1OTM3MWFkaXF6a2N4/document?format=pdf&download=0","read_by":"Companies House REST API (filing history)","detail":"form SH01; category capital","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"C-ObjEO34ZQfZew15OwdbyY1nVfRgjW2qPamJ4tK7YH0T8y3Bb2lwvwui1IAvANL1b7GSN9yjJWI_A9Jm2GFBA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-08-03","event_type":"corporate_action","title":"Admission of Further Securities to Trading","rns_category":"Admission of Further Securities to Trading","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/admission-of-further-securities-to-trading/9702000","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"tUf0OjRFILSjDSoP2NZw9Xh07bKEBKNkegMagGVcTd8RPpSiRJhRVqB7Gcshc21WWUltgxcwSEgnuLhnfNG7Cw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-08-03","event_type":"corporate_action","title":"Total Voting Rights","rns_category":"Total Voting Rights","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/total-voting-rights/9701955","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"3-E3uLoLok03PY4FjcU4inmFBulRCR57KZE_jI4wvyr62tPBnCKlymgBnGnr0u150aUcqR2CaZ3mExJ6hrCZDg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-07-31","event_type":"regulatory_announcement","title":"Datroway approved in EU for TNBC","rns_category":"Datroway approved in EU for TNBC","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/datroway-approved-in-eu-for-tnbc-/9697891","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"cRP6McSi7Xn1Z8BgeXGCbXasgSLJB6eeKnVC-ySITXC5KxER4dVaxJwk_0oMY4wh9MKgKelFAPRG7BJrQ3oFDw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-07-27","event_type":"regulatory_announcement","title":"Update on Ultomiris Phase III trial in HSCT-TMA","rns_category":"Update on Ultomiris Phase III trial in HSCT-TMA","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/update-on-ultomiris-phase-iii-trial-in-hsct-tma/9687921","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"xWAd_lxYoBsa_VpLPi1i318As80sup-7-1UurJYTZtHJ-HdjwsQC6zkNmTss5gQ6gBbazLFayA8i1yMVSkinAw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-07-27","event_type":"regulatory_announcement","title":"Sone-Ve improved survival in gastric cancers","rns_category":"Sone-Ve improved survival in gastric cancers","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/sone-ve-improved-survival-in-gastric-cancers/9687895","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"BSmuLfZT4SihQkkR9ZakVOX8bZ_Q2Omg1Vm1ZiRtFewr4niIdm4pNxTxvfEovhDeFUeyAehyJZMGjPQaDRchDQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-07-27","event_type":"regulatory_announcement","title":"Half-year Financial Report","rns_category":"Half-year Financial Report","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/half-year-financial-report/9687613","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"cQ3JaEjmoLMWUhfUxLb3yyC6t3iqSfia6EsWwaM0ytEBDQr42xrlYgdEG_WLYwKsZyAVJEQR2MCMwK_ezaWRBA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-07-23","event_type":"regulatory_announcement","title":"Etcamah approved in the EU for ER+ breast cancer","rns_category":"Etcamah approved in the EU for ER+ breast cancer","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/etcamah-approved-in-the-eu-for-er-breast-cancer-/9683039","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"Au9uekesbFQEmfCcAl__lX2xig-hN7T8gxSFwivrHZNSQgsuj6polyi13QfX9o0Y5r4jvTMPHwi8vj1LbzirAQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-07-14","event_type":"regulatory_announcement","title":"AstraZeneca licenses novel EGFR inhibitor","rns_category":"AstraZeneca licenses novel EGFR inhibitor","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/astrazeneca-licenses-novel-egfr-inhibitor/9666690","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"OUala9UZz0qNNE9OuRTBR9ZNzAhbRnR0LErCesJVLduG-IGYLzeJRs_NgU14GtpRSigUGwdF-XxU0OU_PlqMBA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-07-09","event_type":"regulatory_announcement","title":"Update on CARDIO-TTRansform Phase III trial","rns_category":"Update on CARDIO-TTRansform Phase III trial","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/update-on-cardio-ttransform-phase-iii-trial/9659738","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"IDQfWPOrU5kbiamwjPLerCUnAvX2NYUvHypTectvvn7lLPHrElbmAz6XQ6NYaSEvQhHNpphVgfWbeTNqgwIlCQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-07-02","event_type":"ch_capital","title":"capital allotment shares — 2026-06-17","ch_filing_type":"capital","source":"Companies House","url":"https://find-and-update.company-information.service.gov.uk/company/02723534/filing-history/MzUyODQ3NzM2N2FkaXF6a2N4/document?format=pdf&download=0","read_by":"Companies House REST API (filing history)","detail":"form SH01; category capital","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"AWJI10QgOnTTYnb6JSaYIEF6JbT96_jqF3KpaeYSOyl3-gV_kz6OKIiLPB607HioXMwKqh3yt-pDstiiGIo_Bg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-07-01","event_type":"corporate_action","title":"Admission of Further Securities to Trading","rns_category":"Admission of Further Securities to Trading","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/admission-of-further-securities-to-trading/9647972","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"CuopYyF8aynXqigdFBh3LcS24q_yNbFmBvkeplquVgy-MFJ7yukWagu5_duxFDQO41mW-yZHR7F1fTgHmBfiCw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-07-01","event_type":"corporate_action","title":"Total Voting Rights","rns_category":"Total Voting Rights","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/total-voting-rights/9647952","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"1gKxqA4sI829JOnUT-y4WNjyJJfN2XUHVTZ6QaXNYRk7t91foF2MAcIA0jX4qIVapjcoZzxN49PsGEsKii75BA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-06-29","event_type":"regulatory_announcement","title":"Enhertu approved in EU for HER2+ solid tumours","rns_category":"Enhertu approved in EU for HER2+ solid tumours","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/enhertu-approved-in-eu-for-her2-solid-tumours/9641178","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"crKUspVSx2yzIJAykdGAb5TsUiXG_St0bjma4eUivi7YcsFbQ6tETK7tzHuxyDUZ9YKqw8FUcdQ9ieBVleXJAQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-06-29","event_type":"regulatory_announcement","title":"Datroway recommended for approval in EU for TNBC","rns_category":"Datroway recommended for approval in EU for TNBC","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/datroway-recommended-for-approval-in-eu-for-tnbc/9640574","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"OQDMHhLRj3mz3-lUmJl5TqaPpcnjVdR5MUS4fSDw_rvous-thu12OdEN3OaQhGgbNTDK1wr02FRG98lyKGZhBg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-06-15","event_type":"regulatory_announcement","title":"Truqap approved in US for prostate cancer","rns_category":"Truqap approved in US for prostate cancer","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/truqap-approved-in-us-for-prostate-cancer-/9617081","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"TJpuFdNk-biRPVUTqI8w1IhqCWACosmBanlEGB9VItJbXuMxoOpB3dhwIGAbN_LgP83NQPXhqzQEWqFYjVKMBQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-06-09","event_type":"ch_capital","title":"capital allotment shares — 2026-05-13","ch_filing_type":"capital","source":"Companies House","url":"https://find-and-update.company-information.service.gov.uk/company/02723534/filing-history/MzUyNTEzNTU5M2FkaXF6a2N4/document?format=pdf&download=0","read_by":"Companies House REST API (filing history)","detail":"form SH01; category capital","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"hm-qMJDyD4oRvf6SlD5j-Ls-Ckew7FZ3mt_UtdM-SIrgDS1PfYPbdo0U2Exb5ZT8BNZ5M_MW44gDg9brNfMMDw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-06-01","event_type":"corporate_action","title":"Admission of Further Securities to Trading","rns_category":"Admission of Further Securities to Trading","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/admission-of-further-securities-to-trading/9595546","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"zInkNbvV25OZbSwGORclrEEiJP-k_sKf-Um0FJoMZvP3G7THoBlKt0ErdBB2b1oy1juYAlhqMjFXkx4NaeLMAg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-06-01","event_type":"corporate_action","title":"Total Voting Rights","rns_category":"Total Voting Rights","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/total-voting-rights/9595518","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"dwr3wVTpT75pjEa0pal4u-9pTDbjLG3LsqS_aFkYGYjU5MAX4q1A9ajoO_w2rAzpTN5S5Q0c1YI5vuTRJM5bBQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-05-29","event_type":"regulatory_announcement","title":"Imfinzi approved in US for early bladder cancer","rns_category":"Imfinzi approved in US for early bladder cancer","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/imfinzi-approved-in-us-for-early-bladder-cancer/9590943","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"Ec9GoeGNTMzrkxthOOxs7oHPPFYdxyPRWqQ-HX6GgwXsBOV3uKo4ROVFlt7znPbV6_ZOYgIpgi3UTjfUukQICQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-05-27","event_type":"ch_confirmation_statement","title":"confirmation statement","ch_filing_type":"confirmation statement","source":"Companies House","url":"https://find-and-update.company-information.service.gov.uk/company/02723534/filing-history/MzUyMzcwNjM3N2FkaXF6a2N4/document?format=pdf&download=0","read_by":"Companies House REST API (filing history)","detail":"form CS01; category confirmation-statement","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"ygDLwZzJ49uQEKAQwkIyrwiabrH055liPnE8Lutc2FjHw0HkFS_gbcs2gWekqG-snjTL9igXe7FcK1FBBlhcCQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-05-27","event_type":"regulatory_announcement","title":"US FDA decision date on camizestrant extended","rns_category":"US FDA decision date on camizestrant extended","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/us-fda-decision-date-on-camizestrant-extended/9586504","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"iBtbA_tfKl91h9jxEnEnyaSJTZ6hjONNcIFsZfRoCpJY2Fbc80LnMxwHGQACJlirIgT7usiRaXURjV2j4dn5Dw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"uk-cm-kg/LSE/AZN","date":"2026-05-26","event_type":"regulatory_announcement","title":"Enhertu recommended in EU for HER2+ solid tumours","rns_category":"Enhertu recommended in EU for HER2+ solid tumours","wire":"RNS","source":"Regulatory announcement via Investegate (RNS)","url":"https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/enhertu-recommended-in-eu-for-her2-solid-tumours/9583995","read_by":"investegate.co.uk company page (RNS mirror)","detail":"RIS source RNS","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"_HUZyCoX3wPJj4ucRf-FzckthEC2StSEj-4RyQcsXxa56UKQG8X63Lrw6HYp3XpgR8aYApNtGN5cGevqc-58CQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}}],"events_signed":"allooloo-cmr-2026-10"}